Today the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization for Johnson & Johnson’s Janssen COVID-19 vaccine—marking the culmination of a year of extraordinary innovation and collaboration by the people of Johnson & Johnson.
I know I speak on behalf of all of us when I say how proud and grateful we are for this opportunity to contribute our single-shot vaccine to the global effort to defeat COVID-19.
Just as the FDA’s decision reflects the urgency of the situation, we are moving forward without delay to ensure we can make the maximum possible impact with our vaccine.
After much hard work and preparation, Johnson & Johnson is ready to join the fight on the ground against COVID-19 and eager to help bring this pandemic to an end—not just in the United States, but throughout the world.
As we continue to pursue regulatory authorization around the world, our company is on track to meet our manufacturing goals, committed to making our vaccine available on a not-for-profit basis for pandemic emergency use and confident in the strength of the data from our clinical trials. Tested at the height of the pandemic, our vaccine has shown its potential to significantly reduce the burden of severe disease with just one immunization.
After much hard work and preparation, Johnson & Johnson is ready to join the fight on the ground against COVID-19 and eager to help bring this pandemic to an end—not just in the United States, but throughout the world.
